“POST-COVID-19 PRICING POLICIES AND THEIR IMPACT ON MEDICATION ACCESSIBILITY: INSIGHTS FROM PHARMACY AND EXECUTIVE-MEDICAL ADMINISTRATION"

Background: The COVID-19 epidemic has profoundly impacted worldwide healthcare systems, exposing considerable difficulties in pharmaceutical pricing and accessibility, especially in low- and middle-income nations. Aim: This study aims to analyse the effects of post-COVID-19 pharmaceutical pricing regulations on the worldwide availability of medicines, emphasising supply chain resilience and equitable access. Methods:A theme analysis of 21 qualitative studies was performed to discern principal trends and challenges in pricing and supply chains. The study examined the effects of policies across several geographical settings. Results: Findings demonstrate that whereas specific pricing strategies have contributed to cost stabilisation and enhanced drug accessibility, considerable discrepancies persist. The pandemic revealed weaknesses in supply networks, resulting in shortages and price escalations, particularly for critical pharmaceuticals and personal protective equipment. Conclusions: Adaptive pricing methods, improved local manufacturing, and resilient supply chain infrastructures are imperative to guarantee sustainable healthcare provision. Recommendations encompass adopting value-based pricing structures, enhancing transparency, and promoting international collaboration to improve health fairness and preparedness for future emergencies.